Vol. 3 No. 7 (2023)
Reimbursement Reviews

Crisantaspase Recombinant (Rylaze)

Published July 11, 2023

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses crisantaspase recombinant (Rylaze), solution for intramuscular injection, 10 mg/0.5 mL (20 mg/mL).
  • Indication: Indicated as a component of a multidrug chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma in adult and pediatric patients 1 year or older who have developed hypersensitivity to Escherichia coli–derived asparaginase.